COMMUNIQUÉS West-GlobeNewswire

Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
19/08/2026
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026 Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas aeruginosa -colonised [...]
Nasus Pharma Announces Transition of Chief Financial Officer
19/08/2026
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative [...]
Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders
19/08/2026
Novartis Venture Fund joins Kynexis’ existing investor syndicate, supporting the Company’s vision of becoming a leading late-stage cognition company Financing supports Phase 2 close-out activities and preparation for [...]
Grey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in Florida
19/08/2026
VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Lungpacer Medical Nominated for 2026 Prix Galien USA Award for Best Medical Technology
19/08/2026
Nomination by the Prix Galien Foundation recognizes the AeroPace® System, the first FDA-approved diaphragm neurostimulation therapy to help critically ill patients breathe on their own again EXTON, Pa., Aug. 19, 2026 ( [...]
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
19/08/2026
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to [...]
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
19/08/2026
Strategic investment by pharmaceutical executive and life sciences investor Michael Porter TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a [...]
SK pharmteco célèbre l’avancement des travaux par une cérémonie d’inauguration de deux sites de production de pointe sur son campus de Swords, en Irlande
19/08/2026
L’événement souligne une importante augmentation de la capacité de production commerciale d’API de petites molécules et l’ouverture d’une nouvelle unité de production à l’échelle du kilogramme, conforme aux BPF, dédiée [...]
Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care
19/08/2026
Applied Biologics believes continued investment in high-quality clinical research is essential to advancing patient care SCOTTSDALE, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
19/08/2026
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026 Presentation will provide additional analysis from the Phase IIa study of RESP-X in Pseudomonas aeruginosa -colonised [...]
Rakovina Therapeutics Announces Results from 2026 Annual General Meeting
19/08/2026
VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is [...]
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
19/08/2026
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio ® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in [...]
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
18/08/2026
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/08/2026
FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase [...]
Acquisition of Own Shares
18/08/2026
Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Iridex Reports Second Quarter 2026 Financial Results
18/08/2026
MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
18/08/2026
Event and Webcast to be held August 20th, 2026, 9:00 AM ET MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated [...]
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
18/08/2026
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/08/2026
WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]

Pages